Maximally precise combinations to overcome metallo-β-lactamase-producing Klebsiella pneumoniae
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00770-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Jan Naseer Kaur und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Diseases Next Generation Therapeutics, University at Buffalo, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, beta-Lactamases, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).
Abstract (Originalsprache)
Gram-negatives harboring metallo-β-lactamases (MBLs) and extended-spectrum β-lactamases (ESBLs) pose a substantial risk to the public health landscape. In ongoing efforts to combat these “superbugs,” we explored the clinical combination of aztreonam and ceftazidime/avibactam together with varying dosages of polymyxin B and imipenem against Klebsiella pneumoniae ( Kp CDC Nevada) in a 9-day hollow fiber infection model (HFIM). As previously reported by our group, although the base of aztreonam and ceftazidime/avibactam alone leads to 3.34 log 10 fold reductions within 72 hours, addition of polymyxin B or imipenem to the base regimen caused maximal killing of 7.55 log 10 and 7.4 log 10 fold reduction, respectively, by the 72-hour time point. Although low-dose polymyxin B and imipenem enhanced the bactericidal activity as an adjuvant to aztreonam +ceftazidime/avibactam, regrowth to ~9 log 10 CFU/mL by 216 hours rendered these combinations ineffective. When aztreonam +ceftazidime/avibactam was supplemented with high-dose polymyxin B and or low-dose polymyxin B + imipenem, it resulted in effective long-term clearance of the bacterial population. Time lapse microscopy profiled the emergence of long filamentous cells in response to PBP3 binding due to aztreonam and ceftazidime. The emergence of spheroplasts via imipenem and damage to the outer membrane via polymyxin B was visualized as a mechanism of persister killing. Despite intrinsic mgrB and bla NDM-1 resistance, polymyxin B and β-lactam combinations represent a promising strategy. Future studies using an integrated molecularly precise pharmacodynamic approach are warranted to unravel the mechanistic details to propose optimal antibiotic combinations to combat untreatable, pan-drug-resistant Gram-negatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Infectious Diseases Next Generation Therapeutics, University at Buffalo, Buffalo, New York, USA.
- School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA.
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
ORCID-Profile: Jan Naseer Kaur, Barry Kreiswirth, Liang Chen, Nicholas M Smith, Brian T Tsuji
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
Zitieren
APA
Kaur, J. N., Klem, J. F., Liu, Y., Boissonneault, K. R., Holden, P. N., Kreiswirth, B., Chen, L., Smith, N. M., & Tsuji, B. T. (2024). Maximally precise combinations to overcome metallo-β-lactamase-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00770-24
Vancouver
Kaur JN, Klem JF, Liu Y, Boissonneault KR, Holden PN, Kreiswirth B, et al. Maximally precise combinations to overcome metallo-β-lactamase-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00770-24
BibTeX
@article{Kaur2024,
author = {Kaur, Jan Naseer and Klem, Jack F and Liu, Yang and Boissonneault, Katie Rose and Holden, Patricia N and Kreiswirth, Barry and Chen, Liang and Smith, Nicholas M and Tsuji, Brian T},
title = {Maximally precise combinations to overcome metallo-β-lactamase-producing Klebsiella pneumoniae},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00770-24}
}
EUVIMED